Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics, Inc. (NASDAQ:NEO) announced that it will release its first quarter 2023 financial results on May 8, 2023, followed by a webcast and conference call at 4:30 p.m. Eastern Time. Interested investors can join the call via telephone or access it through the company's Investor Relations website. The company specializes in cancer genetics testing and offers a wide range of oncology-focused testing services. NeoGenomics operates CAP accredited and CLIA certified laboratories across the United States and internationally, serving a diverse clientele in the oncology field. This upcoming financial announcement is crucial for investors tracking the company's performance and strategic initiatives.
NeoGenomics, Inc. (NASDAQ: NEO), a prominent provider of cancer-focused genetic testing and oncology contract research services, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 11:00am ET. A live audio webcast will be accessible via the Investor Relations section of their website.
NeoGenomics specializes in cancer genetics testing, offering a wide range of testing options to assist healthcare providers in diagnosing and treating cancer. The company also supports pharmaceutical clients through clinical trials and drug development.
Headquartered in Fort Myers, Florida, NeoGenomics operates accredited laboratories across the U.S. and internationally. They are dedicated to connecting patients with transformative therapies while ensuring compliance with data protection laws.
NeoGenomics, Inc. (NASDAQ:NEO) has announced plans to present nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. The presentations will showcase data on the company's advanced RaDaR liquid biopsy test, designed for detecting minimal residual disease (MRD). Dr. Shashikant Kulkarni, Chief Scientific Officer, highlighted the performance comparisons of RaDaR against other MRD tests, emphasizing the firm's commitment to innovation in cancer monitoring. Each abstract covers various aspects of cancer testing, including new methodologies and technological advancements in the field. RaDaR has received FDA Breakthrough Device Designation and is validated for use across multiple cancer types, enhancing NeoGenomics' service portfolio for oncologists and pharmaceutical partners.
NeoGenomics, Inc. (NASDAQ:NEO) will host an Investor Day on April 4, 2023, starting at 8:00 am ET, featuring presentations and a Q&A session with its executive team. Pre-registration is available here. The live event will be webcasted on the investor relations page at ir.neogenomics.com, with a replay accessible for 30 days post-event. Based in Fort Myers, FL, NeoGenomics specializes in oncology testing and services, aiming to facilitate cancer diagnosis and treatment through advanced genetics testing and data protection compliance.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
